Shenyang Sunshine Pharmaceutical Co. Ltd.

University of Michigan

Cancer Research Technology Limited

Agouron Pharmaceuticals, Inc.

Jiangsu Ascentage Biomed Development Inc.

Ascenta Therapeutics, Inc.

Pfizer Corporation

Ming Guo

Yunlong Zhou

Yu Jing

Lingling Jiao

Ping Min

Guangfeng Wang

Suixiong Cai

Shaomeng Wang

Jianyong Chen

John F W Keana

Liu Liu

Donna McEachern

Chao-Yie Yang

Bennett C Borer

Dajun Yang

Longchuan Bai

Jan-Jon Chu

Shuguang Zhu

Jia Liu

Naresh Nayyar

Zhen-Ping Wu

Yi Li

Laure Navarre

Mark Bryan Mitchell

Xu Qian

Régis Périon

Aparna Nadig Srirangam

Bennett Chaplin Borer

A compound of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein Rand Rare independently H; Ris selected from H, a C-Cstraight-chain, and a branched or cyclic alkyl; and R, R, R, R, and Rare each independently selected from C-Calkyl, halo C-Calkyl and the like. Also provided is a method for preparing the compound, pharmaceutical compositions including the compound or pharmaceutically acceptable salts thereof, and uses of the compound or pharmaceutically acceptable salt thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO. 

Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof

A compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, a preparation method thereof and a pharmaceutical use thereof are provided. In particular, the compound has the following Formula (I), wherein Rand Rare each independently H; Ris H or C-Calkyl; Ar is an aromatic ring or a heteroaromatic ring selected from a naphthalene ring, a pyridine ring, a thiophene ring, a furan ring and a substituted benzene ring. Pharmaceutically acceptable salts of the present compound, are provided, as well as uses of the compound or pharmaceutically acceptable salts thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO. 

Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof

Disclosed are a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, a preparation method thereof, pharmaceutical compositions and uses thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO, wherein in the formula (I), Rand Rare each independently hydrogen; Ris hydrogen or Calkyl; and Ar is an aromatic ring or an heteroaromatic ring selected from a naphthalene ring, a pyridine ring, a thiophene ring, a furan ring and a substituted benzene ring. 

Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryl or heteroaryl, preparation method thereof and pharmaceutical use thereof

Disclosed herein are certain indoloquinolone compounds, methods of preparation thereof, pharmaceutical compositions thereof, and uses thereof, such as their uses as ALK inhibitors.

Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors

This invention relates to a process for preparing R-gossypol L-phenylalaninol dienamine using non-chromatographic purification methods. In particular, the invention is directed to resolution of R- and S-gossypol L-phenylalaninol dienamine by crystallization. R-gossypol L-phenylalaninol dienamine is a useful intermediate for the preparation of R-(&#x2212;)-gossypol and R-(&#x2212;)-gossypol acetic acid co-crystal. R-(&#x2212;)-Gossypol acetic acid and its co-crystal is useful for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death.

Process for preparing R-gossypol L-phenylalaninol dienamine

This invention relates to relates to methods for producing gossypol acetic acid co-crystals and (&#x2212;)-gossypol acetic acid co-crystals. The invention also relates to pharmaceutical compositions comprising gossypol acetic acid co-crystals and (&#x2212;)-gossypol acetic acid co-crystals and the use of gossypol acetic acid co-crystals and (&#x2212;)-gossypol acetic acid co-crystals for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death.

Production of gossypol co-crystals

The present invention relates to novel polymorphic and amorphous forms of a phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.

Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-ce]indol-6-one

Growing community of inventors

San Diego, CA, United States of America

Ming Guo